Article | Published:

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia

Nature Medicine volume 21, pages 335343 (2015) | Download Citation

Abstract

Rearrangements of MLL (encoding lysine-specific methyltransferase 2A and officially known as KMT2A; herein referred to as MLL to denote the gene associated with mixed-lineage leukemia) generate MLL fusion proteins that bind DNA and drive leukemogenic gene expression. This gene expression program is dependent on the disruptor of telomeric silencing 1–like histone 3 lysine 79 (H3K79) methyltransferase DOT1L, and small-molecule DOT1L inhibitors show promise as therapeutics for these leukemias. However, the mechanisms underlying this dependency are unclear. We conducted a genome-scale RNAi screen and found that the histone deacetylase SIRT1 is required for the establishment of a heterochromatin-like state around MLL fusion target genes after DOT1L inhibition. DOT1L inhibits chromatin localization of a repressive complex composed of SIRT1 and the H3K9 methyltransferase SUV39H1, thereby maintaining an open chromatin state with elevated H3K9 acetylation and minimal H3K9 methylation at MLL fusion target genes. Furthermore, the combination of SIRT1 activators and DOT1L inhibitors shows enhanced antiproliferative activity against MLL-rearranged leukemia cells. These results indicate that the dynamic interplay between chromatin regulators controlling the activation and repression of gene expression could provide novel opportunities for combination therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    & The language of covalent histone modifications. Nature 403, 41–45 (2000).

  2. 2.

    & Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708 (2014).

  3. 3.

    et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593–599 (2000).

  4. 4.

    , & Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 109, 745–756 (2002).

  5. 5.

    et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 150, 613–632 (1998).

  6. 6.

    et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12, 1052–1058 (2002).

  7. 7.

    et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823–837 (2007).

  8. 8.

    et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).

  9. 9.

    et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 28, 2825–2839 (2008).

  10. 10.

    , & The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 16, 92–106 (2007).

  11. 11.

    et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24, 574–589 (2010).

  12. 12.

    et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110, 4445–4454 (2007).

  13. 13.

    et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167–178 (2005).

  14. 14.

    , , , & Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCα in an aldosterone-sensitive manner. J. Biol. Chem. 281, 18059–18068 (2006).

  15. 15.

    , , & Characterization of the DOT1L network: implications of diverse roles for DOT1L. Protein J. 29, 213–223 (2010).

  16. 16.

    , , , & Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed-lineage leukemia (MLL) fusion proteins. J. Biol. Chem. 288, 30585–30596 (2013).

  17. 17.

    et al. Human histone H3K79 methyltransferase DOT1L protein [corrected] binds actively transcribing RNA polymerase II to regulate gene expression. J. Biol. Chem. 287, 39698–39709 (2012).

  18. 18.

    & The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. 7, 283–301 (2012).

  19. 19.

    , , , & Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117, 4759–4768 (2011).

  20. 20.

    , , & DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117, 6912–6922 (2011).

  21. 21.

    et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27, 813–822 (2013).

  22. 22.

    et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121, 2533–2541 (2013).

  23. 23.

    et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70, 10234–10242 (2010).

  24. 24.

    et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355–368 (2008).

  25. 25.

    & A role for DOT1L in MLL-rearranged leukemias. Epigenomics 3, 667–670 (2011).

  26. 26.

    et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22, 3403–3408 (2008).

  27. 27.

    & Homeobox genes in leukemogenesis. Int. J. Hematol. 71, 301–308 (2000).

  28. 28.

    et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26, 896–908 (2014).

  29. 29.

    et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011).

  30. 30.

    et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017–1025 (2013).

  31. 31.

    et al. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J. Med. Chem. 55, 8066–8074 (2012).

  32. 32.

    et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288 (2012).

  33. 33.

    et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm. Drug Dispos. 35, 237–252 (2014).

  34. 34.

    et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharmacol. Exp. Ther. 350, 646–656 (2014).

  35. 35.

    Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793–798 (2000).

  36. 36.

    et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16, 93–105 (2004).

  37. 37.

    et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283–1298 (2006).

  38. 38.

    , , , & Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3, 715–719 (2006).

  39. 39.

    Sirtuins inhibitors: the approach to affinity and selectivity. Biochim. Biophys. Acta 1804, 1635–1644 (2010).

  40. 40.

    et al. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 450, 440–444 (2007).

  41. 41.

    et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell 133, 627–639 (2008).

  42. 42.

    et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. USA 102, 1859–1864 (2005).

  43. 43.

    , , , & Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013).

  44. 44.

    et al. Small-molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007).

  45. 45.

    et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 6, 836–843 (2014).

  46. 46.

    et al. Reconstitution of yeast silent chromatin: multiple contact sites and O-AADPR binding load SIR complexes onto nucleosomes in vitro. Mol. Cell 33, 323–334 (2009).

  47. 47.

    , , , & Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. Proc. Natl. Acad. Sci. USA 100, 1820–1825 (2003).

  48. 48.

    et al. Dot1 and histone H3K79 methylation in natural telomeric and HM silencing. Mol. Cell 42, 118–126 (2011).

  49. 49.

    et al. Mechanism for epigenetic variegation of gene expression at yeast telomeric heterochromatin. Genes Dev. 26, 2443–2455 (2012).

  50. 50.

    , , & Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800 (2000).

  51. 51.

    & Facultative heterochromatin: is there a distinctive molecular signature? Mol. Cell 28, 1–13 (2007).

  52. 52.

    et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159, 558–571 (2014).

  53. 53.

    , & Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48, 491–507 (2012).

  54. 54.

    et al. Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenance. J. Exp. Med. 210, 987–1001 (2013).

  55. 55.

    et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Rep. 7, 1239–1247 (2014).

  56. 56.

    et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 124, 121–133 (2014).

  57. 57.

    et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute Myeloid Leukemia stem cells. Cell Stem Cell 15, 431–446 (2014).

  58. 58.

    et al. The DOT1L Inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood 124, 387 (2014).

  59. 59.

    et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006).

  60. 60.

    et al. An assessment of histone-modification antibody quality. Nat. Struct. Mol. Biol. 18, 91–93 (2011).

  61. 61.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

  62. 62.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  63. 63.

    & iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS ONE 7, e31690 (2012).

Download references

Acknowledgements

We would like to thank J. Bradner for providing EPZ4777, and J. Brady and Z. Feng for administrative assistance. This work was supported by the Leukemia and Lymphoma Society, by Gabrielle's Angel Research Foundation and by US National Institutes of Health grant nos. CA66996, CA140575 and CA176745 (to S.A.A.).

Author information

Affiliations

  1. Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

    • Chun-Wei Chen
    • , Richard P Koche
    • , Amit U Sinha
    • , Aniruddha J Deshpande
    • , Nan Zhu
    • , Rowena Eng
    • , Haiming Xu
    • , Scott H Chu
    • , Xi Wang
    • , Christopher Delaney
    •  & Scott A Armstrong
  2. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.

    • John G Doench
    • , David E Root
    • , William C Hahn
    •  & James E Bradner
  3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

    • Jun Qi
    • , William C Hahn
    •  & James E Bradner
  4. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.

    • Kathrin M Bernt

Authors

  1. Search for Chun-Wei Chen in:

  2. Search for Richard P Koche in:

  3. Search for Amit U Sinha in:

  4. Search for Aniruddha J Deshpande in:

  5. Search for Nan Zhu in:

  6. Search for Rowena Eng in:

  7. Search for John G Doench in:

  8. Search for Haiming Xu in:

  9. Search for Scott H Chu in:

  10. Search for Jun Qi in:

  11. Search for Xi Wang in:

  12. Search for Christopher Delaney in:

  13. Search for Kathrin M Bernt in:

  14. Search for David E Root in:

  15. Search for William C Hahn in:

  16. Search for James E Bradner in:

  17. Search for Scott A Armstrong in:

Contributions

C.-W.C. and S.A.A. conceived the study and wrote the paper; R.P.K. and A.U.S. conducted genome-wide data analyses; A.J.D. and N.Z. performed ChIP-seq experiments; R.E., S.H.C., H.X., X.W. and C.D. performed molecular biology, cell culture and animal experiments; J.G.D., D.E.R. and W.C.H. processed shRNA library screens; K.M.B. generated the Dot1l mouse model and conceived experiments; J.Q. and J.E.B. synthesized and supplied EPZ4777 and provided conceptual input.

Competing interests

S.A.A. is a consultant for Epizyme, Inc. The remaining authors report no competing financial interests.

Corresponding author

Correspondence to Scott A Armstrong.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–12.

  2. 2.

    Supplementary Tables 2-3

    Supplementary Tables 2–3

Excel files

  1. 1.

    Supplementary Table 1

    Supplementary Tables 1

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.3832